GERN heads into its May 6 Q1 earnings call with short interest climbing fast and a history of punishing post-print moves.
Short sellers have been adding aggressively. Short interest has risen 8% over the past week to 14.7% of the free float — up from roughly 12.8% just five sessions ago on April 23, the sharpest single-week jump in the past two months. Over the past month the position has grown 10%, and FINRA's latest fortnightly figure puts reported short shares above 82 million. At 3.57 days to cover, a meaningful squeeze would take time to unwind. What makes the build notable is where it's happening in the cycle: shorts are being added ahead of a catalyst event with a painful track record.
The lending market does not, however, reinforce the urgency the short-interest numbers imply. Borrow availability remains ample — availability has actually loosened dramatically over the past six weeks, with the lending pool now sitting near its most comfortable level of the past year, far removed from the 52-week trough. Cost to borrow has spiked over the past week, roughly doubling to 0.53%, but that starting level was so low that even the doubling leaves it well inside easy-borrow territory. The divergence is worth naming: short interest is building, but the borrow market is relaxed, suggesting the shorts are not being squeezed into their positions by supply constraints — they're choosing to be there.
Options positioning tells a mildly more cautious story, though not an alarmed one. The put/call ratio has edged up to 0.46, about 1.4 standard deviations above its 20-day average of 0.45 — elevated by historical standards for this name, which has swung from a 52-week PCR high of 0.57 down to a low of 0.05. The current reading is closer to the cautious end of that range, but the move from the 20-day mean is modest. Options traders are adding a little protection, but not pricing in a crisis.
The Street backdrop gives the bears more ammunition than the bulls. Analyst data in this snapshot is dated — the most recent change on file is from Needham in November 2025, when Gil Blum trimmed his target from $5 to $4 while holding a Buy rating. Goldman Sachs reinstated with a Sell and a $1.00 target last July. With the stock at $1.51, only the Goldman target sits at or below current levels; the consensus mean of $4.00 implies 165% theoretical upside, though those figures largely predate the February 2026 earnings collapse and should be treated cautiously. The bull case centres on the EU approval of Rytelo (imetelstat) for low-risk MDS and the potential to diversify revenue as physician education drives uptake. Bears point to flat near-term revenues, the IMpactMF trial readout pushed to the second half of 2026, and a trail of negative-to-neutral analyst actions over the past year.
The recent earnings history gives context to the current short build. At the last print on February 25-26, the stock fell 15% on the day and extended losses to nearly 25% over the following five sessions. That pattern explains the positioning: 15% short interest into a print with a recent track record of double-digit drawdowns is a rational if aggressive stance. The May 6 release therefore becomes less a test of whether Rytelo sales are growing and more a question of whether management can frame the IMpactMF timeline and EU commercial ramp in a way that breaks the negative post-earnings pattern — with a heavily rebuilt short base watching closely.
See the live data behind this article on ORTEX.
Open GERN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
